RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-4788
Malaria parasiteP. yoelii
Genotype
DisruptedGene model (rodent): PY17X_1424200; Gene model (P.falciparum): PF3D7_0715900; Gene product: cation diffusion facilitator family protein, putative
Phenotype Gametocyte/Gamete;
Last modified: 12 June 2020, 18:26
  *RMgm-4788
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption
Reference (PubMed-PMID number) Reference 1 (PMID number) : 32273496
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. yoelii
Parent strain/lineP. y. yoelii 17XNL
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherJiang Y, Yuan J
Name Group/DepartmentState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network
Name InstituteSchool of Life Sciences, Xiamen University
CityXiamen, Fujian
CountryChina
Name of the mutant parasite
RMgm numberRMgm-4788
Principal nameΔ1424200
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/Gametenormal production of gametocytes; normal exflagellation
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot tested
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of PY17X_1424200

Protein (function)
To identify membrane proteins critical in sensing XA or transducing XAinduced signal during gametogenesis, we identified 59 P. yoelii genes that are expressed in gametocytes and encode proteins with 1 to 22 predicted transmembrane domains (TMs) from the PlasmoDB database. We designed single guide RNA (sgRNA) to disrupt each of these genes using CRISPR/Cas9 methods16,17 and were able to successfully knockout (KO) 45 (76%) of the genes in the P. yoelii 17XNL strain, obtaining at least two cloned lines for each mutant . The remaining 14 genes (24%) were refractory to repeated deletion attempts using three independent sgRNA sequences, suggesting their essential roles for asexual blood-stage growth. The 45 gene deletion mutants proliferated asexually in mouse blood normally and were able to produce both male and female gametocytes although the gametocytemia level varied among these mutants.
Next we measured the gametogenesis of male gametocyte by counting exflagellation centers (ECs) formed in vitro after stimulation with 50 μMXAat 22 °C.Only one mutant (PY17X_1116300; GEP1) showed complete deficiency in EC formation and male gamete release and this mutant was analysed in greater detail.

Phenotype

Blood stage growth, gametocytemia and exflagellation was analysed.

Normal asexual blood stage growth/multiplication; normal production of gametocytes; normal exflagellation

Additional information

Other mutants
See other mutants generated in this study


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PY17X_1424200
Gene Model P. falciparum ortholog PF3D7_0715900
Gene productcation diffusion facilitator family protein, putative
Gene product: Alternative name
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct usedCRISPR/Cas9 construct: integration through double strand break repair
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationCRISPR/Cas9 plasmid pYCm was used for all the genetic modifications. For gene deleting, 5’-genomic and 3’-genomic segments (400 to 700 bp) of the target genes were amplified as left and right homologous arms, respectively, using gene specific primers. The PCR products were digested with appropriate restriction enzymes and the digested products were inserted into matched restriction sites of pYCm
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6